A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
8位分析师一窥Integra Lifesciences的专家展望
Analysts' ratings for Integra Lifesciences (NASDAQ:IART) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
8位分析师提供的分析师对Integra Lifesciences（纳斯达克股票代码：IART）在上个季度的评级从看涨到看跌不等。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Integra Lifesciences, presenting an average target of $33.5, a high estimate of $49.00, and a low estimate of $24.00. Observing a downward trend, the current average is 23.2% lower than the prior average price target of $43.62.
在评估12个月目标股价时，分析师公布了对Integra Lifesciences的见解，平均目标股价为33.5美元，最高估计为49.00美元，低估值为24.00美元。从下降趋势来看，目前的平均价格比之前的平均目标价43.62美元低23.2％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析师评级：全面细分
A comprehensive examination of how financial experts perceive Integra...
对金融专家如何看待...
登录免费看全文
登录/注册